药品名称 | ADENOSCAN | 申请号 | 020059 | 产品号 | 001 | 活性成分 | ADENOSINE | 市场状态 | 停止上市 | 剂型或给药途径 | SOLUTION;IV (INFUSION) | 规格 | 60MG/20ML (3MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or efficacy reasons** | 治疗等效代码 | | 参比药物 | 否 | 批准日期 | 1995/05/18 | 申请机构 | ASTELLAS PHARMA US INC
| 化学类型 | New indication | 审评分类 | Standard review drug |
|
|
|
与本品相关的市场独占权保护信息 | 独占权代码 | 失效日期 | 无 | 历史市场独占权保护信息 | 无 |
|
与药品注册相关的信息 | 申请号 | 修订号 | 审批结论 | 公开文档类型 | 文档创建时间 | 获取文档 | 020059 | 018 | AP | Letter | 2014/08/21 | 下载 | 020059 | 018 | AP | Label | 2014/08/22 | 下载 | 020059 | 017 | AP | Label | 2014/08/22 | 下载 | 020059 | 017 | AP | Letter | 2014/08/21 | 下载 | 020059 | 016 | AP | Letter | 2014/01/07 | 下载 | 020059 | 016 | AP | Label | 2014/01/07 | 下载 | 020059 | 014 | AP | Label | 2009/11/19 | 下载 | 020059 | 014 | AP | Letter | 2010/01/19 | 下载 | 020059 | 011 | AP | Letter | 2005/07/21 | 下载 | 020059 | 007 | AP | Letter | 2001/08/31 | 下载 | 020059 | 007 | AP | Label | 2003/04/30 | 下载 | 020059 | 007 | AP | Review | 2004/05/25 | 下载 | 020059 | 000 | AP | Other Important Information from FDA | 2013/12/27 | 下载 |
|
药品注册审批历史信息 | 申请号 | 修订号 | 审批结论 | 审批日期 | 审批内容 | 020059 | 018 | AP | 2014/08/20 | Labeling Revision | 020059 | 017 | AP | 2014/08/20 | Labeling Revision | 020059 | 016 | AP | 2014/01/03 | Labeling Revision | 020059 | 015 | AP | 2013/12/09 | Manufacturing Change or Addition | 020059 | 014 | AP | 2009/11/06 | Labeling Revision | 020059 | 011 | AP | 2005/07/14 | Labeling Revision | 020059 | 008 | AP | 2000/02/01 | Manufacturing Change or Addition | 020059 | 007 | AP | 2001/08/31 | Efficacy Supplement with Clinical Data to Support | 020059 | 006 | AP | 1999/10/26 | Control Supplement | 020059 | 005 | AP | 1998/09/22 | Manufacturing Change or Addition | 020059 | 004 | AP | 1997/12/10 | Labeling Revision | 020059 | 003 | AP | 1997/01/07 | Control Supplement | 020059 | 002 | AP | 1996/10/02 | Manufacturing Change or Addition | 020059 | 001 | AP | 1995/06/26 | Control Supplement | 020059 | 000 | AP | 1995/05/18 | Approval |
|